Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. MU
5. ACN
6. NVDA
7. IBM
8. PRIM
9. SPY
10. DPZ

Go back to Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
(NASDAQ: MRNS) Delayed: 0.55 --0 (-0%)
Previous Close $0.55    52 Week High $8.12 
Open $0.55    52 Week Low $1.02 
Day High $0.55    P/E N/A 
Day Low $0.55    EPS $0.00 
Volume 1,500